ImpediMed Balance Sheet Health
Financial Health criteria checks 5/6
ImpediMed has a total shareholder equity of A$9.0M and total debt of A$20.9M, which brings its debt-to-equity ratio to 231.3%. Its total assets and total liabilities are A$38.4M and A$29.3M respectively.
Key information
231.29%
Debt to equity ratio
AU$20.87m
Debt
| Interest coverage ratio | n/a |
| Cash | AU$18.85m |
| Equity | AU$9.02m |
| Total liabilities | AU$29.34m |
| Total assets | AU$38.36m |
Recent financial health updates
We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Recent updates
IPD: Equity Raise And New CEO Will Support Future Rebound
Analysts have revised their ImpediMed valuation, with the fair value estimate moving from A$0.10 to A$0.03 as they apply a higher discount rate, assume slightly lower revenue growth, factor in a higher profit margin, and use a much lower future P/E multiple in their models. What's in the News for ImpediMed ImpediMed scheduled a Special and Extraordinary Shareholders Meeting for June 11, 2026, at Clifford Chance in Sydney, to seek investor approval for multiple share, option, and follow on option issuances across placement tranches, a share purchase plan, Trafalgar Capital, and Christine Emmanuel Donnelly or nominee.We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Financial Position Analysis
Short Term Liabilities: IPD's short term assets (A$25.7M) exceed its short term liabilities (A$6.9M).
Long Term Liabilities: IPD's short term assets (A$25.7M) exceed its long term liabilities (A$22.5M).
Debt to Equity History and Analysis
Debt Level: IPD's net debt to equity ratio (22.4%) is considered satisfactory.
Reducing Debt: IPD's debt to equity ratio has increased from 0% to 231.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IPD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IPD is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/27 14:45 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImpediMed Limited is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Williamson | Bell Potter |
| Martyn Jacobs | Bell Potter |
| Shane Storey | Canaccord Genuity |